News

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger agreement.

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the Centurion Vision System with Active Sentry.

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

We ask leading experts in the field what eye disease they would cure and why.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Viridian plans to submit a biologics license application (BLA) for VRDN-003 by year-end 2026.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.

Researchers conducted this study to determine how often and why spontaneous soft drusen regresses without atrophy in patients who had intermediate or atrophic age-related macular degeneration.

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

Researchers will investigate a gene in the eye that is crucial for normal vision, but can cause retinal diseases when mutated that often lead to blindness.

Catch up on this week's highlights in retina.

A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.

We ask leading experts in the field what eye disease they would cure and why.

Leading companies spotlight innovations in cataract and refractive surgery at the 43rd ESCRS Congress in Copenhagen

Immersive VR simulation helps patients better understand intraocular lens options.